HIV Universal Vaccine

Overview

Journal Mol Cell Ther

Specialty Biochemistry

Date 2019 Mar 1

PMID 30815266

Citations 1

Authors

Marek Malecki

Bianka Saetre

Affiliations

Soon will be listed here.

Abstract

Background: For many deadly viruses, there are no preventive and / or therapeutic vaccines approved by health authorities World-wide (e.g., HIV, Ebola, Dengue, and many others). Although, for some viruses, prophylactic vaccines are very effective (e.g., HBV, and many others).In this realm, we design, manufacture, test, and streamline into the clinics novel viral universal vaccines (VUV). VUV have such unique features, that medical vaccination or natural infection induced immunity against some viruses (e.g., HBV) upon the VUV's administration to the infected with other, different viruses patients, is redirected against these other, newly infecting viruses (e.g., HIV).

Specific Aim: The specific aim of this work was biomolecular engineering of the HIV universal vaccine comprising the two main functional domains: CD4 or anti-gp120 - as the HIV tagging domain and HBsAg - as the immune response eliciting domain, so that upon its administration the HBV medical immunization or natural infection induced immunity would be redirected, accelerated, and amplified to fight the HIV infection.

Healthy Donors And Patients: Per the Institutional Review Board approval and in compliance with the Declaration of Helsinki, all healthy donors and patients were presented with the Patients' Bill of Rights and provided Patient Informed Consent. All the procedures were pursued by the licensed medical doctors.

Methods & Results: We have biomolecularly engineered HIV universal vaccine (HIVUV) comprising human CD4 or anti-gp120 and HBsAg of HBV. By immunoblotting and magnetic activated molecular sorting, we have demonstrated high specificity of this vaccine in binding HIV. By flow cytometry and nuclear magnetic resonance, we have demonstrated high efficacy of these vaccines to engage HBV immunized patients' immune system against HIV. Administration of HIVUV to blood or lymph of the HIV+ patients resulted in rapid reduction of the HIV viremia down to undetectable. It also resulted in protection of populations of CD4+ cells against HIV caused decline.

Conclusions: We have demonstrated the proof of concept for high efficacy of VUV, specifically HIVUV, in annihilating HIV. Nevertheless, the same compositions, processes, and methods, for persons skilled in biotechnology, pharmacogenomics, and molecular medicine, are adaptable for other deadly viral infections, which we vigorously pursue.

Citing Articles

HIV Apheresis Tags (HIVAT) Aided Elimination of Viremia.

Malecki M, Saetre B Mol Cell Ther. 2019; 6(1).

PMID: 30931130 PMC: 6438618.

References

Arthos J, Cicala C, Steenbeke T, Chun T, Dela Cruz C, Hanback D . Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J Biol Chem. 2002; 277(13):11456-64. DOI: 10.1074/jbc.M111191200. View

Popovic M, Sarngadharan M, Read E, Gallo R . Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984; 224(4648):497-500. DOI: 10.1126/science.6200935. View

Dalgleish A, Beverley P, Clapham P, Crawford D, Greaves M, Weiss R . The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984; 312(5996):763-7. DOI: 10.1038/312763a0. View

Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K . Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun. 2016; 7:10844. PMC: 4782064. DOI: 10.1038/ncomms10844. View

Gallo D, Kimpton J, Dailey P . Comparative studies on use of fresh and frozen peripheral blood lymphocyte specimens for isolation of human immunodeficiency virus and effects of cell lysis on isolation efficiency. J Clin Microbiol. 1987; 25(7):1291-4. PMC: 269195. DOI: 10.1128/jcm.25.7.1291-1294.1987. View

Krejcarek G, Tucker K . Covalent attachment of chelating groups to macromolecules. Biochem Biophys Res Commun. 1977; 77(2):581-5. DOI: 10.1016/s0006-291x(77)80018-1. View

Kwok S, Mack D, Mullis K, Poiesz B, Ehrlich G, Blair D . Identification of human immunodeficiency virus sequences by using in vitro enzymatic amplification and oligomer cleavage detection. J Virol. 1987; 61(5):1690-4. PMC: 254157. DOI: 10.1128/JVI.61.5.1690-1694.1987. View

Fisher R, Bertonis J, Meier W, Johnson V, Costopoulos D, Liu T . HIV infection is blocked in vitro by recombinant soluble CD4. Nature. 1988; 331(6151):76-8. DOI: 10.1038/331076a0. View

Wain-Hobson S, Sonigo P, Danos O, Cole S, Alizon M . Nucleotide sequence of the AIDS virus, LAV. Cell. 1985; 40(1):9-17. DOI: 10.1016/0092-8674(85)90303-4. View

10.

Malecki M . HER2/NEU GENE EXPRESSION PRODUCTS EVALUATED WITH SUPERPARAMAGNETIC, GENETICALLY ENGINEERED ANTIBODIES. Proc S Dak Acad Sci. 2013; 86:297-308. PMC: 3535833. View

11.

Malecki M, Sabo C, Foorohar A, Tombokan X . Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B. Clin Transl Med. 2016; 5(1):32. PMC: 4990520. DOI: 10.1186/s40169-016-0111-8. View

12.

Gallo R, SARIN P, Gelmann E, Robert-Guroff M, Richardson E, Kalyanaraman V . Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science. 1983; 220(4599):865-7. DOI: 10.1126/science.6601823. View

13.

Barre-Sinoussi F, Chermann J, Rey F, Nugeyre M, Chamaret S, Gruest J . Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983; 220(4599):868-71. DOI: 10.1126/science.6189183. View

14.

Kim J, Excler J, Michael N . Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med. 2014; 66:423-37. DOI: 10.1146/annurev-med-052912-123749. View

15.

Meares C, Goodwin D, Leung C, Girgis A, SILVESTER D, Nunn A . Covalent attachment of metal chelates to proteins:the stability in vivo and in vitro of the conjugate of albumin with a chelate of 111indium. Proc Natl Acad Sci U S A. 1976; 73(11):3803-6. PMC: 431216. DOI: 10.1073/pnas.73.11.3803. View

16.

Malecki M, Hsu A, Truong L, Sanchez S . Molecular immunolabeling with recombinant single-chain variable fragment (scFv) antibodies designed with metal-binding domains. Proc Natl Acad Sci U S A. 2002; 99(1):213-8. PMC: 117541. DOI: 10.1073/pnas.261567298. View

17.

Traunecker A, Luke W, Karjalainen K . Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature. 1988; 331(6151):84-6. DOI: 10.1038/331084a0. View

18.

Molday R, Yen S, Rembaum A . Application of magnetic microspheres in labelling and separation of cells. Nature. 1977; 268(5619):437-8. DOI: 10.1038/268437a0. View

19.

Hodges T, Kahn J, Kaplan L, Groopman J, Volberding P, Amman A . Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Antimicrob Agents Chemother. 1991; 35(12):2580-6. PMC: 245434. DOI: 10.1128/AAC.35.12.2580. View

20.

Malecki M, Putzer E, Quach C, Dodivenaka C, Tombokan X . Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus. Clin Transl Med. 2016; 5(1):44. PMC: 5130937. DOI: 10.1186/s40169-016-0125-2. View